NCT01000792View on ClinicalTrials.gov

3-D Visualization of the Anti-Obstructive Effect of Levocetirizine

PHASE3CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

July 31, 2010

Conditions
Allergic Rhinitis
Interventions
DRUG

Levocetirizine

The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).

DRUG

Levocetirizine

Levocetirizine

Trial Locations (1)

52074

HNO-Praxis Dr. Pasch/Prof. Schlöndorff, Aachen

Sponsors
All Listed Sponsors
lead

Clinical Research International Limited

INDUSTRY